Litcius/Paper detail

Efficacy and safety of KN046, a novel bispecific antibody against PD-L1 and CTLA-4, in patients with non-small cell lung cancer who failed platinum-based chemotherapy: a phase II study

Anwen Xiong, Wei Li, Xingya Li, Yun Fan, Zhiyong Ma, Jian Fang, Qiang Xie, Wu Zhuang, Mafei Kang, Jing Wang, Ting Xu, Mo Xu, Lihua Zhi, Qing Liu, Ni Wang, Caicun Zhou

2023European Journal of Cancer20 citationsDOI

Topics & Concepts

MedicineDiscontinuationInterquartile rangeInternal medicineCohortLung cancerChemotherapyAdverse effectGastroenterologyClinical endpointIncidence (geometry)Confidence intervalClinical trialOncologySurgeryOpticsPhysicsCancer Immunotherapy and BiomarkersLung Cancer Research StudiesLung Cancer Treatments and Mutations
Efficacy and safety of KN046, a novel bispecific antibody against PD-L1 and CTLA-4, in patients with non-small cell lung cancer who failed platinum-based chemotherapy: a phase II study | Litcius